Facts of Iclusig (ponatinib) ?
- Medicine Name: Iclusig
- Generic Name: ponatinib
- Approval Date: 2012
- Company Name: ARIAD Pharmaceuticals, Inc.
- Available as (Form & Strength): Capsules: 1 mg, 2 mg, 3 mg, and 4 mg
Iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy (1). This indication is based upon response rate . There are no trials verifying an improvement in disease-related symptoms or increased survival with Iclusig
Iclusig tablets should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15°to 30° C (59° to 86° F) Keep away from children.